Evidence map›Paper›PMID 40297201›Full record

ArticleTherapeutic advances in gastroenterology2025

Comparative efficacy of subcutaneous infliximab switching in remission and non-remission patients with inflammatory bowel disease after intravenous maintenance: 1-year outcome from a multicentre cohort study.

June Hwa Bae, Yoo Jin Lee, Jung-Bin Park, Ji Eun Baek, Seung Wook Hong, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

June Hwa BaeDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Yoo Jin LeeDepartment of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea.
Jung-Bin ParkDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Ji Eun BaekDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Seung Wook HongDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Sang Hyoung ParkDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.ORCID https://orcid.org/0000-0002-5366-5749
Dong-Hoon YangDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Byong Duk YeDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.ORCID https://orcid.org/0000-0001-6647-6325
Jeong-Sik ByeonDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Seung-Jae MyungDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Suk-Kyun YangDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.ORCID https://orcid.org/0000-0003-2772-2575
Kyeong Ok KimDepartment of Internal Medicine, Yeungnam University College of Medicine, Daegu, South Korea.
Byung Ik JangDepartment of Internal Medicine, Yeungnam University College of Medicine, Daegu, South Korea.
Eun Soo KimDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.
Hyeong Ho JoDepartment of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, South Korea.
Eun Young KimDepartment of Internal Medicine, Daegu Catholic University School of Medicine, 33 Duryugongwon-ro 17 gil, Namgu, Daegu 42472, South Korea.
Sung Wook HwangDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea.ORCID https://orcid.org/0000-0002-6981-7575

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Elective switching from intravenous (IV) to subcutaneous (SC) infliximab (IFX) has shown efficacy in patients with inflammatory bowel disease (IBD). However, long-term outcomes for patients not in remission remain unclear. Objectives: We evaluated the effectiveness of SC IFX switching in both remission and non-remission patients. Design: This study was a retrospective multicentre study conducted across five tertiary hospitals in Korea. Methods: Patients with IBD who switched to SC IFX between January 2021 and January 2023 were included. Clinical remission was defined as a Crohn's Disease Activity Index of <150 or a partial Mayo score of <2. Biochemical remission was defined as faecal calprotectin of <250 µg/g and C-reactive protein of <0.5 mg/dL. We investigated the treatment persistence rate of SC IFX and trends in pharmacokinetics, clinical indices and biomarkers over 1 year of follow-up, analysing the data based on the baseline remission state. Results: Among 127 patients included, 90 (70.9%) were in clinical remission, and 37 (29.1%) were not at the time of switching. The one-year treatment persistence rate was 92.1%, with no significant difference between the clinical remission and non-remission groups ( Conclusion: Switching from IV to SC IFX during maintenance therapy demonstrated high treatment persistence and safety, irrespective of clinical and biochemical remission status.

Indexed as

inflammatory bowel diseaseinfliximabremissionsubcutaneous

Identifiers

PMID40297201
PMCPMC12035300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.